Table 1 Association between TNFAIP8 expression levels and clinicopathological characteristics of EOC
TNFAIP8 expression | ||||
|---|---|---|---|---|
Variables | NO.=202 | Low (%) (no.=86) | High (%) (no.=116) | P -value |
Age (years) | ||||
⩽54 | 97 | 45 (46.4) | 52 (53.6) | 0.292 |
>54 | 105 | 41 (39.1) | 64 (60.9) | |
FIGO stage | ||||
I | 15 | 9 (60.0) | 6 (40.0) | 0.068 |
II | 26 | 15 (57.7) | 11 (42.3) | |
III–IV | 161 | 62 (38.5) | 99 (61.5) | |
Histologic grade | ||||
G1/G2 | 76 | 42 (55.3) | 34 (44.7) | 0.005 |
G3 | 126 | 44 (34.9) | 82 (65.1) | |
Histological type | ||||
Serous | 128 | 55 (43.0) | 73 (57.0) | 0.138 |
Mucinous | 29 | 9 (31.0) | 20 (69.0) | |
Endometrioid | 33 | 19 (57.6) | 14 (42.4) | |
Clear cell | 12 | 3 (25.0) | 9 (75.0) | |
Residual tumour size | ||||
⩽1 cm | 168 | 78 (46.4) | 90 (53.6) | 0.014 |
>1 cm | 34 | 8 (23.6) | 26 (76.4) | |
Ascites | ||||
⩽100 ml | 54 | 20 (37.0) | 34 (63.0) | 0.336 |
>100 ml | 148 | 66 (44.6) | 82 (55.4) | |
Serum CA-125 level | ||||
⩽35 U ml−1 | 65 | 25 (38.5) | 40 (61.5) | 0.415 |
>35 U ml−1 | 137 | 61 (44.5) | 76 (55.5) | |
Recurrence | ||||
Yes | 95 | 33 (34.7) | 62 (65.3) | 0.024 |
No | 107 | 53 (49.5) | 54 (50.5) | |
Response to chemotherapy | ||||
Platinum sensitive | 134 | 73 (54.5) | 61 (45.5) | < 0.001 |
Platinum resistant | 46 | 10 (21.7) | 36 (78.3) | |
Platinum refractory | 22 | 3 (13.6) | 19 (86.4) | |
Intraperitoneal metastasis | ||||
Yes | 137 | 50 (36.5) | 87 (63.5) | 0.011 |
No | 65 | 36 (55.4) | 29 (44.6) | |
Lymph node metastasis no.=81 | ||||
Yes | 47 | 15 (31.9) | 32 (68.1) | 0.008 |
No | 34 | 21 (63.6) | 13 (36.4) | |
